AbSci’s Acquisition of Denovium

Goodwin Procter LLP advised AbSci on the deal.

AbSci announced its acquisition of Denovium, Inc.

AbSci is a leading synthetic biology company enabling drug discovery and biomanufacturing of next-generation biotherapeutics.

Denovium is an artificial intelligence company pioneering novel AI methods to accelerate innovation in biopharma.

AbSci will integrate the Denovium Engine into its drug discovery and manufacturing cell line development capabilities and expects to realize near term synergies using AI deep learning to better predict relevant variants and cell line characteristics for each new project. With continued application and further training of the Denovium Engine, AbSci’s vision is to make in silico biologic drug discovery and cell line development a reality. This will enable next-generation therapies to make it to market at unprecedented speeds.

The Goodwin team was led by Maggie Wong (Picture) and included Kingsley Taft, Laurie Burlingame, Mulon Luo, Margaret Beale-Wirsing, Shane Albright, Eugene Shin, Dan Karelitz, Jonathan LaPlante, Lynda Galligan, and Tony Guan.

Involved fees earner: Shane Albright – Goodwin Procter; Margaret Beale-Wirsing – Goodwin Procter; Laurie Burlingame – Goodwin Procter; Lynda Galligan – Goodwin Procter; Daniel Karelitz – Goodwin Procter; Jonathan LaPlante – Goodwin Procter; Mulon Luo – Goodwin Procter; Eugene Shin – Goodwin Procter; Kingsley Taft – Goodwin Procter; Maggie Wong – Goodwin Procter;

Law Firms: Goodwin Procter;

Clients: AbSci;


Author: Ambrogio Visconti